This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma (PBTC-047)

This study is currently recruiting participants.
See Contacts and Locations
Verified November 2016 by Pediatric Brain Tumor Consortium
Information provided by (Responsible Party):
Pediatric Brain Tumor Consortium Identifier:
First received: February 22, 2016
Last updated: November 15, 2016
Last verified: November 2016
This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma that is growing, spreading, or getting worse (progressive). Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Condition Intervention Phase
Glioma Drug: LBH589 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

Resource links provided by NLM:

Further study details as provided by Pediatric Brain Tumor Consortium:

Primary Outcome Measures:
  • To describe the toxicity profile and the dose-limiting toxicities of panobinostat in children with recurrent/progressive DIPG [ Time Frame: 26 courses (approximately 2 years) ]
    Adverse Events

  • To estimate the maximum-tolerated dose and/or the recommended-phase 2 dose of panobinostat in children with recurrent/progressive DIPG [ Time Frame: Course 1 (the first 4 weeks of treatment) ]
    Dose Finding

  • To evaluate pharmacokinetic parameters of apparent volume of the central compartment (Vc/F) [ Time Frame: Course 1, Day 1 and Day 3 sample collections ]
    Plasma Pharmacokinetics

  • To evaluate pharmacokinetic parameters of elimination rate constant (Ke) [ Time Frame: Course 1, Day 1 and Day 3 sample collections ]
    Plasma Pharmacokinetics

  • To estimate pharmacokinetic parameters of half-life (t1/2) [ Time Frame: Course 1, Day 1 and Day 3 sample collections ]
    Plasma Pharmacokinetics

  • To estimate pharmacokinetic parameters of apparent oral clearance (CL/F) [ Time Frame: Course 1, Day 1 and Day 3 sample collections ]
    Plasma Pharmacokinetics

  • To estimate pharmacokinetic parameters of area under the plasma concentration time curve (AUC) [ Time Frame: Course 1, Day 1 and Day 3 sample collections ]
    Plasma Pharmacokinetics

Secondary Outcome Measures:
  • To describe the progression-free survival (PFS) and overall survival (OS) of children with recurrent or progressive DIPG who are treated with panobinostat [ Time Frame: 26 courses (approximately 2 years) ]
    Evaluated Response per imaging or clinical progression

  • To identify histone 3 K27M mutations in peripheral blood and urine, and evaluate changes with treatment. [ Time Frame: Day 1 of courses 1, 2, 4, 6, and 12 ]
    Pharmacodynamics: Cell-free DNA - Blood and Urine (Optional)

Estimated Enrollment: 20
Study Start Date: March 2016
Estimated Study Completion Date: February 2019
Estimated Primary Completion Date: February 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
Patients with recurrent/progressive DIPG will be enrolled at the time of progression. All patients will take the study drug panobinostat (LBH589).
Drug: LBH589
Patients with recurrent/progressive DIPG will be enrolled at the time of progression. Therapy with panobinostat will be administered every other day, 3 times/ week, p.o. preferably on a Monday/Wednesday/Friday schedule for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (total 4 weeks) will constitute one course. Treatment will continue for up to 26 courses (approximately 2 years) barring progressive disease or unacceptable toxicity.
Other Name: Panobinostat

  Show Detailed Description


Ages Eligible for Study:   2 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • DIAGNOSIS - Patients with progressive DIPG, as defined by progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (e.g., anticonvulsant or corticosteroid toxicity wean, electrolyte disturbances, sepsis, hyperglycemia, etc.), OR an increase in the bi-dimensional measurement, taking as a reference the smallest disease measurement recorded since diagnosis, OR the appearance of a new tumor lesion since diagnosis.

    • Please note: patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.
    • Patients with pontine lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of malignant glioma WHO II-IV.
  • AGE - Patients must be ≥ 2 but < 22 years of age at the time of enrollment.
  • BSA

    • Patients must have a BSA ≥ 0.80 m2 for dose 5mg/m2.
    • Patients must have a BSA ≥ 0.65 m2 for doses of 10mg/m2 - 22 mg/m2.
    • Patients must have a BSA ≥ 0.50 m2 for doses of 28 mg/m2 - 36 mg/m2.
  • ABILITY TO SWALLOW - Patient must be able to swallow capsules whole.
  • PERFORMANCE STATUS - Karnofsky Performance Scale (KPS for > 16 years of age) or Lansky Performance Score (LPS for ≤ 16 years of age) assessed within 7 days of enrollment must be ≥ 50%. Patients who are unable to walk because of neurologic deficits, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  • PRIOR THERAPY - Patients must have received a minimum of 54 Gy focal irradiation administered over approximately 42 days prior to enrollment. Patients must have recovered from the acute treatment-related toxicities (defined as < grade 1) of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
  • MYELOSUPPRESSIVE CHEMOTHERAPY - Patients must have received their last dose of known myelosuppressive anticancer therapy or immunotherapy at least 21 days prior to enrollment (42 days if prior nitrosourea).

    • Biologic or investigational agent (anti-neoplastic): Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent ≥ 7 days prior to study enrollment. (For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur, and discussed with the principal investigator.)
    • Monoclonal antibody treatment and agents with known prolonged half-lives: At least three half-lives must have elapsed prior to enrollment. (Note: A list of the half-lives of commonly used monoclonal antibodies is available on the PBTC webpage under Generic Forms and Templates.)
  • RADIATION THERAPY - Patients must have had their last fraction of:

    • Craniospinal irradiation or radiation to ≥ 50% of pelvis > 3 months prior to enrollment.
    • Focal irradiation to the primary site > 42 days prior to enrollment
    • Local palliative irradiation other than previously irradiated primary site (small port) ≥ 14 days
  • ORGAN FUNCTION - Patients must have adequate organ and marrow function as defined below:

    • Absolute neutrophil count ≥ 1,000/mm3
    • Platelets ≥ 100,000/ mm3 (unsupported, defined as no platelet transfusion within 7 days, and recovery from post-transfusion nadir)
    • Hemoglobin ≥ 8 g/dl (may receive transfusions)
    • Total bilirubin ≤ 1.5 times institutional upper limit of normal (ULN)
    • ALT(SGPT) < 3 x institutional upper limit of normal
    • Albumin ≥ 3 g/dl
    • Potassium ≥ LLN
    • Serum total calcium (correct for serum albumin) or ionized calcium ≥ LLN
    • Serum creatinine based on age/gender as noted below. Patients that do not meet the criteria below but have a 24-hour Creatinine Clearance or GFR (radioisotope or iothalamate) ≥ 70 ml/min/1.73 m2 are eligible. Maximum Serum Creatinine for age/gender:

      • Age 2 to < 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female)
      • Age 6 to < 10 years: 1 mg/dL (male); 1 mg/dL (female)
      • Age 10 to < 13 years: 1.2 mg/dL (male); 1.2 mg/dL (female)
      • Age 13 to < 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female)
      • Age ≥ 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)
    • Cardiac Function:

      • Left ventricular ejection fraction ≥ 50 by gated radionuclide study OR shortening fraction of ≥ 27% by echocardiogram
      • Patient has no ventricular arrhythmias except for benign premature ventricular contractions.
      • Patient has a QTc interval < 450 ms.
  • GROWTH FACTORS - Patients must be off all colony-forming growth factor(s) for at least 7 days prior to enrollment (i.e. filgrastim, sargramostim or erythropoietin). 14 days must have elapsed if patients received PEG formulations.
  • FRUIT - Patients must agree to avoid grapefruit or grapefruit juice and Seville (sour) oranges during the entire study.
  • PREGNANCY STATUS - Female patients of childbearing potential must have a negative serum or urine pregnancy test.
  • BREASTFEEDING - Female patients with an infant must agree not to breastfeed their infants while on this study.
  • PREGNANCY PREVENTION - Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after the last dose of panobinostat.
  • INFORMED CONSENT - The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document according to institutional guidelines.



    • Patients who have had > 60 Gy total radiation to the pons (e.g. patients who have received re-irradiation).
    • Patients have had prior HDAC, DAC, HSP90 inhibitors for the treatment of their DIPG.
    • Patients have had valproic acid within 28 days prior to enrollment.
    • Patients have had prior bone marrow transplant.
  • NEUROLOGICAL STATUS - Patients have significant acute deterioration in neurologic status in 72 hours prior to enrollment, in the opinion of the treating physician.

    • Patients have impairment of GI function or GI disease that may significantly alter the absorption of panobinostat; for example severe inflammatory bowel disease.
    • Patients have diarrhea > CTCAE grade 2.
  • SYSTEMIC ILLNESS - Patients have any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the ability of the patient to tolerate protocol therapy or put them at additional risk for toxicity or would interfere with the study procedures or results.
  • OTHER MALIGNANCY - Patients have a history of any other malignancy.
  • TRANSFUSIONS - Patients are known to be refractory to red blood cell or platelet transfusions.

    • Patients who are receiving any other anticancer or investigational drug therapy
    • Patients who are required to receive any medication which can prolong the QTc interval. Please see Protocol Appendix B: Medications Which May Cause QTc Prolongation.
  • INABILITY TO PARTICIPATE - Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02717455

Contact: Emily Carps, MBA, CCRA 901-595-5762
Contact: Stacye Richardson, MSHS, CCRP 901-595-3783

United States, California
Children's Hospital Los Angeles Recruiting
Los Angeles, California, United States, 90026
Contact: Girish Dhall, MD    323-361-4629   
Contact: Kelley Haley, BSN,RN,CCRP    323-361-2480   
Principal Investigator: Girish Dhall, MD         
Stanford University and Lucile Packard Children's Hospital Recruiting
Palo Alto, California, United States, 94304
Contact: Paul Graham Fisher, MD    650-721-5889   
Contact: Leah White    650-725-4708   
Principal Investigator: Paul Graham Fisher, MD         
United States, District of Columbia
Children's National Medical Center Recruiting
Washington, District of Columbia, United States, 20010
Contact: Roger Packer, MD    202-884-2120   
Contact: Chad Stephans    202-476-4481   
Principal Investigator: Roger Packer, MD         
United States, Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago Recruiting
Chicago, Illinois, United States, 60611
Contact: Stewart Goldman, MD    312-227-4844   
Contact: Emily Golbeck    312-227-4858   
Principal Investigator: Stewart Goldman, MD         
United States, Maryland
National Cancer Institute Not yet recruiting
Bethesda, Maryland, United States, 20892
Contact: Kathy Warren, MD    301-435-4683   
Contact: Sonja Crandon, RN,BSN,PMP    301-496-8009   
Principal Investigator: Kathy Warren, MD         
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Ira Dunkel, MD    212-639-2153   
Contact: Ryan Turner    646-888-5723   
Principal Investigator: Ira Dunkel, MD         
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Maryam Fouladi, MD    513-803-0721   
Contact: CCHMC Cancer Line    513-636-2799   
Principal Investigator: Maryam Fouladi, MD         
United States, Pennsylvania
Children's Hospital of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Contact: Arthur 'Kim' Ritchey, MD    412-692-6794   
Contact: Sharon DiBridge    412-692-7070   
Principal Investigator: Arthur 'Kim' Ritchey, MD         
United States, Tennessee
St. Jude Children's Research Hospital Recruiting
Memphis, Tennessee, United States, 38105
Contact: Alberto Broniscer, MD    901-595-4925   
Contact: Dillon Robinson    901-595-5922   
Principal Investigator: Alberto Broniscer, MD         
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Patricia Baxter, MD    832-824-4681   
Contact: Susan Burlingame, CCRP    832-824-1532   
Principal Investigator: Patricia Baxter, MD         
Sponsors and Collaborators
Pediatric Brain Tumor Consortium
Principal Investigator: Michelle Monje, MD, Phd Stanford University
  More Information

Responsible Party: Pediatric Brain Tumor Consortium Identifier: NCT02717455     History of Changes
Obsolete Identifiers: NCT02899715
Other Study ID Numbers: PBTC-047
Study First Received: February 22, 2016
Last Updated: November 15, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Pediatric Brain Tumor Consortium:
Diffuse Intrinsic Pontine Glioma

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017